ABSTRACT: Osteoarthritis (OA) is a common chronic disease, causing joint pain and reduced physical function. OA progresses slowly over a period of several years; to avoid an exacerbation of symptoms, it is critical to able to diagnose the disease as early as possible. The identification of disease-specific biomarkers may enable such an early diagnosis. The aim of this study was to investigate potential biomarkers of cartilage metabolism in OA using a targeted multiplex approach by single reaction monitoring. Intact looking cartilage of femoral heads from patients with OA (n ¼ 9) or femoral neck fractures (n ¼ 12) was examined. Variations and relative quantifications of 35 selected extracellular matrix (ECM) proteins were analyzed using nano-LC coupled to tandem mass spectrometry. Our study showed statistically significantly increased levels of asporin (ASPN), mimecan (MIME), matrilin-3 (MATN3), cartilage intermediate layer protein 2 (CILP-2), collagen VI, collagen II, and collagen III N-propeptide in OA cartilage compared with non-OA cartilage. The other proteins in the protein panel did not appear to be different between the two groups. In conclusion, we identified a number of cartilage matrix proteins which may represent early molecular changes in the OA process and may have potential to predict the development of OA. ß
Osteoarthritis (OA) combines structural joint changes and patient symptoms. Structural changes have traditionally been identified as joint space narrowing and presence of osteophytes using radiographic examination and in recent research studies also by MRI. [1] [2] [3] However, radiographic and MRI changes are not well related to symptoms 4 and they generally appear when molecular changes in cartilage have already reached a point of no return. We urge to identify pre-radiographic biomarkers of disease when molecular changes are still reversible. This is further supported by the fact that radiographic OA changes develop over a long period of time, 10-15 years. Our lack of understanding for the underlying sequential molecular mechanisms of OA pathogenesis may explain the shortage of diagnostic tools in early stages of the disease. As a result, current therapeutic managements are focused on relieving patient symptoms by strengthening supporting structures, analgesics, and anti-inflammatory treatments and ultimately surgical procedures, that is, total joint replacements. Accordingly, a major objective in OA research has become the discovery of specific biomarkers of cartilage degeneration, as a major characteristic of disease, to facilitate early diagnostics, and new mechanism-related molecular treatments. 5 An increasing number of studies have examined normal and OA articular cartilage, in humans and animals, to shed light on biology and composition of cartilage and the pathological processes leading to OA. [6] [7] [8] [9] They suggest that the degradation and release of molecules from cartilage to body fluids varies according to status and severity of the pathological process. It has been shown that for example, the concentration of released cartilage oligomeric protein (COMP) may indicate the severity of the disease. 10 Together, the biomarker studies have gradually increased our understanding of pathophysiology and underlying mechanisms of disease. Encouraged by these findings, recent studies have focused on the identification of new markers, more specifically addressing early diagnosis, and the development of new targets for disease modifying drugs. 5, [11] [12] [13] Furthermore, biomarkers may also be a means to predict disease progression and optimize individual treatments. 14 The aim of this study was to explore candidate proteins in early events of osteoarthritic cartilage which may predict development of OA. We used targeted proteomics and liquid chromatography coupled with mass spectrometry LC-MS. The biomarker panel used for targeted MS was the same as described elsewhere, 16 representing number of extracellular matrix (ECM) proteins known to be important for tissue structure and function.
PATIENTS AND METHODS
This was an analytic case-control study (Level III Evidence). Cartilage samples were taken from patients at the operation of total hip replacement due to primary OA (case) or femoral neck fracture (control). Nine patients in OA group (age rang 50-80 years, 5 women) and 12 patients in control group (age range 53-94 years, 7 women) were included in the study. Fracture patients had no history of joint problems. Macroscopically intact full-depth cartilage with an area of approximately 1 Â 1 cm 2 was dissected from the posterior part each femoral head. The samples were stored at À20 C until use. The cartilage was treated as described elsewhere. 17 In brief, the cartilage pieces were powderized, extracted by 4M GuHCl and 50 ml of the extract was undergone reduction, alkylation, ethanol precipitation, and then digested by trypsin (2 mg) Promega (Madison, WI). Thereafter, 10 mL aliquots of the digested samples were passed through an ultrafiltration filter, Pall 30 kDa (PALL Life Sciences, Nanosep MI) to remove large GAG-containing peptides followed by desalting on a spin column C18 (Nest Group, MA). The elution by 50% acetonitrile (with 0.1% formic acid) was transferred into an MS vial, dried in Speed Vac, and resuspended in 0.2% formic acid before running through TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, Waltham, MA) equipped with an easy nano-LC system (Thermo Scientific).
We used a targeted multiplex approach using single reaction monitoring with 74 optimized SRM assays, representing 35 ECM proteins. The biomarker panel used for targeted MS was the same as described elsewhere 16 (Supplementary Table S1 ). The combination of a peptide precursor mass together with a fragment mass (Q1/Q3) is called a transition and we used 3-5 transitions for each selected peptide. Duplicate injections for each sample were made and relative quantifications were performed using synthetic peptide standards, which also ensured identification a peptide by means of their expected retention times and their transitions. The peak area was defined as the summed peak area from all transitions of that peptide. A peak was assigned in a chromatogram when the ratio between signal to noise (S/N) was at least 3, that is, the lowest level of detection (LOD). The values lower than LOD were considered undetectable; and the half of the LOD was taken as a peak area value for them.
Skyline software (MacCoss Lab, University of Washington) was used to identify peptides and quantify peak intensities. The ratios of the peak areas in chromatograms were used to compare the relative abundance of selected peptides
The experiment was approved by the Ethical review board (742/2004) and informative consents were obtained from patients.
Statistics
We used the area under the ROC-curve (AUROC), calculated using logistic regression, to describe the predictive accuracy of the peptides. The Mann-Whitney U-test was used to test the null hypothesis that the AUROC was 0.5, that is, equivalent to flipping a coin. 18, 19 To overcome the problem of multiple testing we used the False Discovery Rate approach (FDR), which controls the expected proportion of false discoveries, that is, rejected true null hypotheses with greater power than conventional Bonferroni correction.
The calculations failed to provide reliable results for two peptides representing tenascin-X because of insufficient variability or too few observations. Matrilin-1, osteopontin, and SPRC were also excluded because of insufficient number of findings detected in our experiment.
RESULTS
The comparison of the 35 selected extracellular proteins by MRM between the two groups showed some specific difference between OA and non-OA human hip cartilage. Seven of the 35 proteins were more abundant in OA cartilage. Expression level of proteins asporin (ASPN), mimecan (MIME), matrilin-3 (MATN3), cartilage intermediate layer protein 2 (CILP2), collagen VI, collagen II, collagen III Npropeptide were significantly higher in OA cartilage compared with non-OA cartilage (Supplementary Table S1 ). The chromatographic peak and the MRM data obtained from a mimecan peptide is presented in Figure 1 . The elevated levels of matrilin-3 in OA cartilage is shown in Figure 2 . Matrilin-1 (MATN1), osteopontin (OSTP), SPARC, and tenascin-X (TENX) were excluded as described above.
The other proteins did not appear to have any predictive ability.
DISCUSSION AND CONCLUSIONS
To our knowledge, this is the first targeted and multiplex proteomic study is performed on these numbers of human OA, and non-OA hip cartilage samples.
Indeed, we show that a multiplexed targeted mass spectrometry approach can be used to differentiate protein abundance in non-OA and OA cartilage. Accordingly, the study identifies novel potential biomarkers for diagnostic and therapeutic purposes. Specifically, our findings are relevant and provide new insight into understanding of the early events in OA pathogenesis since the sampled cartilage was fulldepth and macroscopically intact. As a study showed that the changes in intact looking cartilage, far from a remote lesion, differed from those in lesions and the changes may represent earlier stages of OA. 20 Therefore, study of OA cartilage due to sampling method can lead to different results.
Proteomics technology has become a powerful tool in biomarker research area and its development during the last decades has made tissue proteomics available even for cartilage. However, there are challenges in cartilage proteomics. Highly abundant proteins, that is, collagens can compromise the detection of low abundant proteins and highly anionic macromolecules, that is, GAGs (aggrecan) can interfere with protein separation due to ionic interactions. In this study, we extracted most of the non-collagenous proteins with yields of 80-100% from articular cartilage 17 while the major part of the collagens were excluded due to their unextractability in our experimental conditions.
Aside collagen and aggrecan there are also small groups of other molecules, which play important roles in ECM and cell-matrix interactions. Small leucine rich proteoglycans (SLRPs) is a group of biologically active components, which reside in the ECM and contribute in collagen fibrilogenesis, molecule cross bridging, and matrix-cell cross talk. 21 This study shows increased amount of ASPN and mimecan in OA compared with non-OA cartilage.
Previous human studies showed the presence of ASPN in articular cartilage 19 and more abundant in superficial layer of articular cartilage. 16 However, its presence was more prominent in meniscus than cartilage of femur, tibia, humerus, trachea, and intervertebral disc. 17 Our study shows increased amount of ASPN in macroscopically normal appearing cartilage of OA hip cartilage compared with normal cartilage while in a study performed on knee cartilage, ASPN in intact looking cartilage, adjacent to OA lesions, was not significantly different from normal knee cartilage. 22 Different findings might be related to differences in either the investigated joint (knee vs. hip) or different methodology used in this study. The studies suggest involvement of ASPN in OA pathogenesis as increased expression of ASPN was also reported in OA cartilage compared with normal cartilage, 23, 24 however, its precise mechanism is poorly understood. Potential mechanisms may be associated with the negative regulatory role of ASPN on TGF-beta function and collagen mineralization. 24 Mimecan (MIME), a member of class III SLRPs was present differently in various cartilage tissues; highest content in femur compared with humerus, tibia, meniscus, rib, trachea, and intervertebral disc. 17 A proteomic study on healthy, unwounded, and wounded cartilage of OA femoral heads revealed increased release of MIME in the conditioned media of unwounded and wounded zones compared with healthy cartilage in OA joint. 7 Increased expression of matrilin-3 was reported in OA and it was correlated with disease severity. 25 Similarly, in this study, we detect higher MATN3 in OA than non-OA cartilage. It is suggested that matrilin-3 (MATN3) possibly contributes in defense mechanism through different signaling pathways to limit inflammation and maintains the tensile and elastic strength of cartilage tissues through different pathways. 26 CILP2, glycoprotein, is generated by chondrocytes and enriched in the intermediate to deep zone of mature articular cartilage. The ultrastructural studies demonstrated that CILP-2 may be associated with collagen VI containing supra structures. 27 This study and other studies revealed increased amount of CILP2 in osteoarthritic human cartilage. 28, 29 Of five peptides representing CILP2 in this study, the difference between OA and non-OA cartilage is only seen in the content of peptide located in very N-terminal of the molecule (99-111 sequence), that is, CILP2-1. This could indicate that the protein was subject to partial degradation by proteases. 
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We showed increased amount of collagen VI in OA cartilage. Collagen VI is a major constituent of pericellular matrix suggested as a transducer of biochemical and mechanical signals for chondrocytes. As animal studies in knockout mice showed altered mechanical property of chondrocytes which led to OA progression. 30 Increased level of COL VI may have protective effect for chondrocytes.
Elevated collagen II and III also reported in previous OA studies 31, 32 and we showed similar results targeting mainly the newly synthesized protein (the N/ C-propeptides). However, general studies of the collagen family requires different methodology as the major collagen network is poorly extracted under the current study conditions. 7, 28 Nonetheless, the peptides found to be more abundant in OA from collagen II and III represents the N-or C-propeptides suggesting these to be newly synthesized, perhaps as an attempt of repair.
In our examination of 35 proteins, we were able to sort out seven potential candidates to be biomarkers for detection of early matrix compositional changes in OA. These seven peptides, more abundant in OA than non-OA cartilage, may have predictive value and eventually be used for diagnosis, prognosis and following response to treatment in OA patients. Yet, further study is required to assess the values of these markers in longitudinal studies.
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